Clinical Trial Update: Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers [Phase 2]

View source ↗

Summary

Phase-2 study of dacomitinib in EGFR-driven advanced solid tumours, including non-small cell lung cancer and head and neck squamous cell carcinoma, is currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Dacomitinib (dacomitinib)

Snippet

Sponsor: National Cancer Centre, Singapore | Conditions: Advanced Solid Tumours, Non-small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING